Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Yabe

Showing results (91-100 of 253) with videos related to

Pageof 26
Sort By:
Internal Medicine (Tokyo, Japan)|June 4, 2010
The role of family nutritional support in Japanese patients with type 2 diabetes mellitusKoin Watanabe, Takeshi Kurose, Naomi Kitatani, et al.
Diabetes, Obesity & Metabolism|September 10, 2025
Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trialsMasashi Hasebe, Chen-Yang Su, Yamato Keidai, et al.
Expert Opinion on Drug Safety|October 29, 2021
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsKeizo Kanasaki, Shen Qu, Fumiko Yamamoto, et al.
Journal of Diabetes Investigation|August 14, 2024
Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practiceYuichiro Yamada, Daisuke Yabe, Kenichiro Shide, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 20, 2020
Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA<sup>®</sup> TrialHirotaka Watada, Hiroyuki Sakamaki, Daisuke Yabe, et al.
Diabetes, Obesity & Metabolism|August 9, 2017
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetesYutaka Seino, Yasuo Terauchi, Takeshi Osonoi, et al.
Diabetes|August 28, 2024
Glucagon Stimulation Test and Insulin Secretory Capacity in the Clinical Assessment of Incretin-Based Therapy for DiabetesTakuya Haraguchi, Yuji Yamazaki, Hitoshi Kuwata, et al.
Journal of Diabetes Investigation|September 4, 2019
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case reportMegumi Yasuda, Katsumi Iizuka, Takehiro Kato, et al.
Genesis (New York, N.Y. : 2000)|April 26, 2007
Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARPDaisuke Yabe, Hitoshi Fukuda, Misayo Aoki, et al.
Diabetes, Obesity & Metabolism|January 6, 2021
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trialsYasuo Terauchi, Daisuke Yabe, Hideaki Kaneto, et al.
Pageof 26

Showing results (91-100 of 253) with videos related to

Sort By:
Pageof 26
Internal Medicine (Tokyo, Japan)|June 4, 2010
The role of family nutritional support in Japanese patients with type 2 diabetes mellitusKoin Watanabe, Takeshi Kurose, Naomi Kitatani, et al.
Diabetes, Obesity & Metabolism|September 10, 2025
Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trialsMasashi Hasebe, Chen-Yang Su, Yamato Keidai, et al.
Expert Opinion on Drug Safety|October 29, 2021
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsKeizo Kanasaki, Shen Qu, Fumiko Yamamoto, et al.
Journal of Diabetes Investigation|August 14, 2024
Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practiceYuichiro Yamada, Daisuke Yabe, Kenichiro Shide, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 20, 2020
Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA<sup>®</sup> TrialHirotaka Watada, Hiroyuki Sakamaki, Daisuke Yabe, et al.
Diabetes, Obesity & Metabolism|August 9, 2017
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetesYutaka Seino, Yasuo Terauchi, Takeshi Osonoi, et al.
Diabetes|August 28, 2024
Glucagon Stimulation Test and Insulin Secretory Capacity in the Clinical Assessment of Incretin-Based Therapy for DiabetesTakuya Haraguchi, Yuji Yamazaki, Hitoshi Kuwata, et al.
Journal of Diabetes Investigation|September 4, 2019
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case reportMegumi Yasuda, Katsumi Iizuka, Takehiro Kato, et al.
Genesis (New York, N.Y. : 2000)|April 26, 2007
Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARPDaisuke Yabe, Hitoshi Fukuda, Misayo Aoki, et al.
Diabetes, Obesity & Metabolism|January 6, 2021
Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trialsYasuo Terauchi, Daisuke Yabe, Hideaki Kaneto, et al.
Pageof 26